Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
Status:
Withdrawn
Trial end date:
2021-01-12
Target enrollment:
Participant gender:
Summary
This is a double blind, placebo controlled, randomized trial to evaluate the safety and
preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid
agonist therapy. Patients will be randomized to two arms: (1) ANS-6637 for three months vs
(2) Placebo for three months. Subjects will subsequently be followed for an additional one
month post treatment.